Results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s (AZN) Imfinzi in combination with ...
Preliminary trial results demonstrated that Imfinzi plus chemo improved event-free survival in resectable early-stage gastric ...
Swiss Mountaineer Dani Arnold breaks the record for the quickest ascent of the north face of the Matterhorn mountain in the Alps. The 1,100 meter-high climb usually takes mountain climbers between ...
Imfinzi is one of AstraZeneca’s key growth drivers for 2025, with potential approvals in stomach and bladder cancers. The ...
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...
This storybook, car-free village is nestled in a small valley at the base of the Matterhorn, the iconic 14,692-foot, hooked-shaped Alpine crag that looms mystically over a rugged snow-draped landscape ...
MATTERHORN is the first global phase 3 trial to show improved event-free survival with an immunotherapy combo vs standard ...
Victory Ventures, in collaboration with Matterhorn Venture Partners, proudly announces the acquisition of a 22,500 ...
The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback